Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Leukemia/Bone Marrow Transplant Program of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, Canada.
J Mol Diagn. 2020 Apr;22(4):571-578. doi: 10.1016/j.jmoldx.2020.01.008. Epub 2020 Feb 6.
NOTCH1 is recurrently mutated in chronic lymphocytic leukemia (CLL), most commonly as a 2-bp frameshift deletion (c.7541_7542delCT). This mutated allele encodes a truncated form of the receptor (p.P2514Rfs∗4) lacking the C-terminal proline, glutamic acid, serine, and threonine (PEST) degradation domain that increases NOTCH1 signaling duration. NOTCH1 mutation has been associated with poor clinical outcomes in CLL. We validated a highly sensitive and quantitative droplet digital PCR assay for the NOTCH1 delCT mutation, which was anticipated to perform well compared with Sanger sequencing and allele-specific PCR. Performance characteristics of this assay were tested on 126 samples from an unselected CLL cohort and a separate cohort of 85 samples from patients with trisomy 12 CLL. The delCT mutation was detected at allele frequencies as low as 0.024%; 25% of unselected cases and 55% of trisomy 12 cases were positive at the 0.024% detection threshold. Mutational burdens ≥1% were significantly associated with shorter overall survival (OS) in patients with trisomy 12+ disease in multivariate analysis (median OS, 9.1 versus 13 years, with hazard ratio of 2.34; P = 0.031). Mutational burdens <1% correlated with shorter OS in univariate, but not multivariate, analyses. These results suggest that droplet digital PCR testing for NOTCH1 delCT mutation may aid in risk stratification and/or disease monitoring in certain subsets of patients with CLL.
NOTCH1 是慢性淋巴细胞白血病(CLL)中经常发生突变的基因,最常见的突变为 2 个碱基的移码缺失(c.7541_7542delCT)。这种突变等位基因编码受体的截断形式(p.P2514Rfs∗4),缺失了 C 末端脯氨酸、谷氨酸、丝氨酸和苏氨酸(PEST)降解结构域,从而增加了 NOTCH1 信号的持续时间。NOTCH1 突变与 CLL 的不良临床结果有关。我们验证了一种针对 NOTCH1 delCT 突变的高度敏感和定量的数字 PCR 检测方法,预计该方法与 Sanger 测序和等位基因特异性 PCR 相比表现良好。该检测方法的性能特征在一个未经选择的 CLL 队列的 126 个样本和另一个来自三体 12 CLL 患者的 85 个样本的队列中进行了测试。在等位基因频率低至 0.024%的情况下可以检测到 delCT 突变;在未经选择的病例中,有 25%的病例和在三体 12 病例中,有 55%的病例在 0.024%的检测阈值下为阳性。在多变量分析中,突变负担≥1%与三体 12+疾病患者的总生存(OS)显著相关(中位 OS,9.1 与 13 年,风险比为 2.34;P=0.031)。在单变量分析中,突变负担<1%与 OS 较短相关,但在多变量分析中则不然。这些结果表明,NOTCH1 delCT 突变的数字 PCR 检测可能有助于某些 CLL 患者的风险分层和/或疾病监测。